Global Ornithine-Transcarbamylase Deficiency Market is valued approximately USD XXX million in 2019 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2020-2027. Ornithine-Transcarbamylase Deficiency is an inherited disorder that causes ammonia in the blood which is identified by complete or partial lack of enzyme ornithine trascarbamylase (OTC). The lack of OTC enzyme concludes in excessive accumulation of nitrogen, in form of ammonia in the blood. The deficiency can be treated by nitrogen scavenging agents. Also, the key players are focusing on strategies such as product launch, innovation and merger & acquisition to sustain themselves amidst fierce competition. Rising incidences of obesity, rising binge eating and consumption of junk foods along with the neglect towards regular exercising are some major drivers supplementing the growth of the market during the forecast period of 2020-2027. According to Obesity Update 2017 by Organization for Economic Co-operation and Development (OCED), the obesity levels are anticipated to increase gradually and countries such as United States, England and Mexico would be having major shares of their population suffering with obesity. U.S. with 47%, 39% of total population in Mexico and 35% population of England is projected to be obese by 2030. Also, according to the Organization for Economic Co-operation and Development in 2017, United Kingdom is the most obese country in Western Europe. Additionally, as per the Health at a Glance Report, reveals that approximately 26.9 % of the UK population is obese in 2015. Also, as per the Organization for Economic Co-operation and Development (OECD) report, obesity in United Kingdom has increased by 92% since the 1990's.

The regional analysis of global Ornithine-Transcarbamylase Deficiency market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region due to the availability of well-defined reimbursement policies from private and public health insurance firms, which help provide the extensive research & development activities and easy access to diagnosis. Whereas Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2027.

Major market player included in this report are:
Ultragenyx Pharmaceutical
Ucyclyd Pharma
Horizon Therapeutics plc
OrphanPacific, Inc.
Altis Endurance LLC
Seqens Group
Bausch Health Companies, Inc.
Unicyte AG
Lucane Pharma SA
Promethera Biosciences SA

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:
DTX-301
SEL-313
SHP-641
PRX-OTC
Others
By Application:
Hospital
Clinic
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2017, 2018
Base year - 2019
Forecast period - 2020 to 2027

Target Audience of the Global Ornithine-Transcarbamylase Deficiency Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors